These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8081414)

  • 21. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
    Daly AK; Leathart JB; London SJ; Idle JR
    Hum Genet; 1995 Mar; 95(3):337-41. PubMed ID: 7868129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
    Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
    Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
    [No Abstract]   [Full Text] [Related]  

  • 29. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.
    Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M
    Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.
    Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M
    Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
    Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
    Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
    Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
    Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine.
    Johansson I; Yue QY; Dahl ML; Heim M; Säwe J; Bertilsson L; Meyer UA; Sjöqvist F; Ingelman-Sundberg M
    Eur J Clin Pharmacol; 1991; 40(6):553-6. PubMed ID: 1679392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population.
    Agúndez JA; Ledesma MC; Ladero JM; Benítez J
    Clin Pharmacol Ther; 1995 Mar; 57(3):265-9. PubMed ID: 7697944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.
    Yokoi T; Kosaka Y; Chida M; Chiba K; Nakamura H; Ishizaki T; Kinoshita M; Sato K; Gonzalez FJ; Kamataki T
    Pharmacogenetics; 1996 Oct; 6(5):395-401. PubMed ID: 8946471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.
    Sata F; Sapone A; Elizondo G; Stocker P; Miller VP; Zheng W; Raunio H; Crespi CL; Gonzalez FJ
    Clin Pharmacol Ther; 2000 Jan; 67(1):48-56. PubMed ID: 10668853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
    Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
    Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
    Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
    Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
    Douglas AM; Atchison BA; Somogyi AA; Drummer OH
    Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.